Companies: 10,795·Total market cap: $144.5T
Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWRNASDAQHealthcare● Active
$73.09
$-2.07(-2.75%)
Market Cap$10.3B
P/E Ratio
52W High$82.26
52W Low$14.3
SEC Filings

Arrowhead Pharmaceuticals, Inc. (ARWR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000879407 · ARWR · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
144/A
Latest Form
2026-05-19
Most Recent
1993
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0000879407 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-11-25
Fiscal Year End
Nov 25, 2025
Accession No.
0000879407-25-000029
Primary Document
arwr-20250930.htm
Source: data.sec.gov · CIK 0000879407 · Accession 0000879407-25-000029

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
S-8
2026-05-07
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-06
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-29
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-28
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-24
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-20
View
10-QQuarterly Report
10-Q
2026-02-05
View
8-KCurrent Report
8-K
2026-02-05
View
ARSARS
ARS
2026-01-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-01-27
View
DEF 14AProxy Statement
DEF 14A
2026-01-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-21
View
Showing 1–15 of 545 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000879407  |  Exchange: NASDAQ · Healthcare

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1993. As a Healthcare sector company with CIK 0000879407, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Arrowhead Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Arrowhead Pharmaceuticals, Inc. 10-K was filed on 2025-11-25 for fiscal year ending 2025. Historical ARWR 10-K annual reports are available from 2010 through 2025.

Investors researching Arrowhead Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ARWR SEC Filings · 8 questions

Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Arrowhead Pharmaceuticals, Inc.'s CIK is 0000879407.

ARWR SEC filingsArrowhead Pharmaceuticals, Inc. SEC documentsfind ARWR 10-K